|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 890.7 USD | -1.75% |
|
-0.37% | +1.41% |
| 02:45pm | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
| Apr. 25 | Regeneron Pharmaceuticals Receives a Shareholder Proposal from John Chevedden | CI |
Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc reported a more than tripling of its quarterly profit on Thursday, helped mainly by robust demand for its COVID-19 antibody cocktail.
Net profit rose to $3.1 billion, or $27.97 per share, in the second quarter ended June 30, from $897.3 million, or $7.61 per share, a year earlier.
(Reporting by Dania Nadeem and Amruta Khandekar in Bengaluru; Editing by Sriraj Kalluvila)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.41% | 95.71B | |
| -2.26% | 103B | |
| +0.79% | 22.02B | |
| -17.84% | 20.9B | |
| -9.21% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B | |
| -26.18% | 8.08B |
REGENERON PHARMACEUTICALS, INC. 
